Filing Details

Accession Number:
0001140361-15-037233
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-10-08 17:50:14
Reporting Period:
2015-10-06
Filing Date:
2015-10-08
Accepted Time:
2015-10-08 17:50:14
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
872589 Regeneron Pharmaceuticals Inc REGN Pharmaceutical Preparations (2834) 133444607
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1121404 Sanofi 54, Rue La Boetie
Paris I0 75008
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-10-06 1,965 $470.41 23,099,495 No 4 P Indirect See note
Common Stock Acquisiton 2015-10-06 3,625 $471.64 23,103,120 No 4 P Indirect See note
Common Stock Acquisiton 2015-10-06 2,650 $472.37 23,105,770 No 4 P Indirect See note
Common Stock Acquisiton 2015-10-06 1,000 $473.31 23,106,770 No 4 P Indirect See note
Common Stock Acquisiton 2015-10-06 1,000 $474.27 23,107,770 No 4 P Indirect See note
Common Stock Acquisiton 2015-10-06 700 $476.35 23,108,470 No 4 P Indirect See note
Common Stock Acquisiton 2015-10-06 100 $476.85 23,108,570 No 4 P Indirect See note
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See note
No 4 P Indirect See note
No 4 P Indirect See note
No 4 P Indirect See note
No 4 P Indirect See note
No 4 P Indirect See note
No 4 P Indirect See note
Footnotes
  1. The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.
  2. Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN").
  3. Purchase prices range from $470.00 to $470.99 per share, inclusive.
  4. Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,309,018 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors.
  5. Purchase prices range from $471.00 to $471.94 per share, inclusive.
  6. Purchase prices range from $472.00 to $472.96 per share, inclusive.
  7. Purchase prices range from $473.00 to $473.76 per share, inclusive.
  8. Purchase prices range from $474.01 to $474.45 per share, inclusive.
  9. Purchase prices range from $475.82 to $476.75 per share, inclusive.
  10. Purchase price was $476.85 per share.